Introduction
incidence of early posttraumatic seizures (EPTS) has been estimated to be between 4 and 25%. Anticonvulsants are routinely used in prophylaxis for EPTS. 3 Phenytoin has been extensively used because of its easy administration intravenously and orally. However, it has drawbacks because of its adverse effects such as ataxia and poor glycemic control. Phenytoin also rarely causes other serious adverse effects such as Stevens-Johnson syndrome and anticonvulsant hypersensitivity syndrome. It also induces the hepatic cytochrome P450 system, causing significant drug-drug interactions. Phenytoin also requires laboratory monitoring of serum levels. 4, 5 Levetiracetam is now often used instead of phenytoin due to its better safety profile. The aim of the study was to compare the efficacy and incidence of adverse effects between levetiracetam and phenytoin when used for the prevention of EPTS.
Patients and Methods
This single-blinded, prospective, randomized study included 100 patients, divided equally into two groups. Patients who were admitted during the period from February 1, 2014, to April 30, 2014, were subjected to this study and alternately assigned to either of the groups. Patients with the following conditions, associated with a higher incidence of EPTS, were included in the study, such as, acute subdural hematoma, compound-depressed fractures with underlying contusions, intracerebral hematoma, diffuse axonal injury, significant cerebral contusions, and traumatic subarachnoid hemorrhage (SAH). Patients with preexisting seizure disorders and other pathological brain conditions were excluded from the study. The dose of phenytoin was 18 mg/kg loading dose followed by 5 mg/kg maintenance dose and that of levetiracetam was 20 mg/kg loading dose and 20 mg/kg/d maintenance dose. All the patients in the study were evaluated and managed according to the Brain Trauma Foundation guidelines. Seizure prophylaxis were administered according to the prefixed protocol. Phenytoin serum levels were checked 48 hours after enrollment. The drugs were initially given intravenously and later orally once it could be started. Patients were on medications and observation for a minimum of 7 days subsequent to the injury.
The following data were collected for the patients in the study: age, sex, and mode of injur y, associated comorbidities, and duration of unconsciousness, occurrence of convulsion, Glasgow Coma Scale (GCS) score, and presence of neurological def icits, computed tomographic scan findings, surgical interventions, and the presence of other systemic injuries. The antiepileptic dose, occurrence of adverse effects, occurrence of seizures, and drug levels of phenytoin were monitored.
Descriptive and inferential statistical analysis of the collected data were performed. Student t-test (two-tailed, independent) was used to find the significance of study parameters on continuous scale between the two groups (intergroup analysis) on metric parameters. Chi-square/ Fisher exact test was used to find the significance of study parameters on a categorical scale between the groups. Significance was assessed at 5% level of significance.
Results
During the study period of 3 months, 100 patients with traumatic brain injury (TBI), meeting the inclusion criteria, were alternately assigned to the following two groups: group P and group L. The collected data for both the groups were analyzed and compared. The patients in the two groups were well matched in age (39.72 AE 17.56 years vs. 35.36 AE 15.95 years, p ¼ 0.197); sex (male, 88 vs. 86%, p ¼ 1.000); and other clinical parameters. Causes of head injuries were statistically similar in two groups (p ¼ 0.100) and motor vehicle accident was the most common cause in both the groups; 62% in group L and 80% in group P. Prevalence of comorbidities (diabetes, hypertension, and alcohol abuse) was similar (p ¼ 0.248). GCS score of patients in both groups at admission and after 6, 12, and 24 hours were similar with the p-values of 0.929, 0.833, 0.897, and 0.848, respectively. The type and number of attacks of convulsion (before starting antiepileptics) were statistically similar in the two groups with a p-value of 0.553 and 0.312, respectively. Presence of neurological deficit was similar in the two groups (p > 0.05). Medical management alone was sufficient in 44 patients of group L (44/50) and 46 patients of group P (46/50). The remaining patients required surgical intervention.
Clinical and radiological risk factors for seizures in both groups are shown in ►Table 2. Occurrence of seizure rates after initiating prophylactic anticonvulsants was more in group P (4/50) than group L (1/50), but the difference was not statistically significant (p ¼ 0.362; OR ¼ 0.24; [95% CI: 0.03-2.17]). Only one patient in group L (1/50) had an adverse reaction, that is, sinus bradycardia not attributable to any cranial or cardiac condition. In group P, three patients developed adverse effects, such as hyperglycemia, giddiness, nystagmus, and ataxia necessitating discontinuation of the drug. Levetiracetam appeared to cause fewer adverse effects, but the difference was not statistically significant (p ¼ 0.617, OR ¼ 0.32 (95% CI: 0.03-3.18]). Monitoring of therapeutic levels of phenytoin showed that toxic levels (> 20 µg/mL) were reached in 12.6% of patients in group P (►Tables 1-5).
Discussion
The use of anticonvulsants for the prevention of EPTS is a standard practice for patients with TBI at risk of developing seizures, so as to prevent secondary brain injury pharmacologic PTS prophylaxis is a part of the Brain Trauma Foundation Guidelines.
3 Phenytoin has been extensively used for seizure prophylaxis as it can be administered both intravenously and orally; besides being effective in the control of focal and generalized seizures. In the randomized trial by Temkin et al 6 , patients with TBI (viz., cortical contusion, subdural hematoma, intracerebral hematoma, depressed skull fractures, penetrating brain injury, and patients with GCS score 10) were assigned to Indian Journal of Neurosurgery Vol. 4 No. 3/2015 treatment with either phenytoin or placebo for 1 year, with 2-year follow-up. Only 3.6% of patients who received phenytoin had EPTS as compared with 14.2% in the placebo group. However, there was no significant difference in the two groups at 1 and 2 years follow-up.
Although phenytoin was effective in the prophylaxis of EPTS, it did not lead to any significant improvement in neurological outcome or mortality rate. 5, 6 Hence, the current recommendation for the duration of use of prophylactic anticonvulsants is for the first 7 days. Phenytoin, although widely used, causes several doserelated adverse effects, such as diplopia, ataxia, and loss of glycemic control which can occur even when used for short periods. It is also known to cause idiosyncratic reactions, such as fever, exfoliative skin rash, Stevens-Johnson syndrome, anticonvulsant hypersensitivity syndrome, and Purple glove syndrome. It induces the hepatic cytochrome P450 system, leading to significant drug-drug interactions. Its metabolism follows first-order kinetics at very low blood levels, but when therapeutic range is reached, small increments in administered phenytoin can cause toxicity. This necessitates laboratory monitoring of serum levels. 
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Our study included 100 patients with TBI at risk for developing EPTS, who were equally divided into the two groups, each receiving either phenytoin or levetiracetam. This was a prospective study of admitted patients who were observed for 7 days subsequent to trauma. Such a close observation facilitated detection of all clinical seizures and the adverse effects because of the drugs. The two groups were well matched in all demographic and clinical parameters, so that extraneous factors were less likely to affect the findings. Only one patient on levetiracetam (1/50) and four on phenytoin (4/50) developed EPTS, but there was no significant difference between the two drugs for EPTS prophylaxis (p ¼ 0.362 with OR ¼ 0.24 [95% CI: 0.03-2.17]). Levetiracetam appeared to be safer when the incidence of adverse effects was considered. In group P, three patients had adverse effects as compared with one in group L, but this difference was not statistically significant (p ¼ 0.617 with OR ¼ 0.32 [95% CI: 0.03-3.18]). Hence, levetiracetam is as effective and safe as phenytoin for EPTS prophylaxis. One drawback with phenytoin was that toxic serum drug levels were observed in 12% patients.
Conclusion
Both phenytoin and levetiracetam are similar in their effectiveness when used in prophylaxis for EPTS. However, the adverse effects because of phenytoin were more troublesome with a need to intervene. Besides, there was also a need to monitor phenytoin drug levels. The major drawback for levetiracetam is the higher cost at present. Hence, levetiracetam can be considered a safe alternative in specific situations, such as presence of hyperglycemia, known hypersensitivity or adverse reaction to phenytoin and risk of drug interactions involving phenytoin.
